SM-3321

N/A

Report date: 2023/12/15 14:59:30

Base Information

Drug NameSM-3321
Drug Alias NameSM-3321SM3321
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionLow affinity immunoglobulin gamma Fc region receptor III-A agonists
TargetsLow affinity immunoglobulin gamma Fc region receptor III-A
Therapy Area/IndicationsLeukemia, Myeloid, AcuteNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhuhai StarMab BioMed Technology Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZhuhai StarMab BioMed Technology Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A